[xls] · web viewdpr korea dr congo ecuador egypt el salvador equatorial guinea eritrea estonia...

WHO TB data collection form for strategies and notifications in 2006, treatment outcomes of cases registered in 2005, and financial information for fiscal years 2006-2008.

To access the WHO global TB database, see www.who.int/tb/country

I1 Country Ethiopia

I2 Date

National TB control programme manager or equivalent: Person filling out this form (if different from name at left)I3 Name Dr Wenimagene Getachew I9 Mr Worku NegusuI4 Functional Title A/ TLCT TEAM LEADER I10 DATA MANAGER, TBL, TB/HIV AND SURVILLANCEI5 Address I11

I6 Telephone251-1-53 05 08 I12 251-1-53 05 08

I7 Fax251-1-51 93 66 I13 251-1- 51 93 66

I8 [email protected] I14 [email protected]

Identification (please update as necessary)

We estimate that it takes about two hours to answer the questions that ask for information about the implementation of the Stop TB Strategy in your country (sheet "S-trategy"). Most of the questions require Yes/No responses only. The time required to answer the questions about epidemiological and financial data will depend on how data are managed at the national level.

Please send your completed form to your local/regional WHO office NOT LATER THAN 1 August, 2007

If you cannot reply to all of the questions before the deadline, please fill in the form as much as possible and send it to us; you can provide the remaining data later on.

MINISTRY OF HEALTH ADDIS ABABAP.O. BOX 1234 WORLD HEALTH ORGANIZATION, COUNTRY OFFICE OF

ETHIOPIA, P.O.BOX 3069, ADDIS ABABA, ETHIOPIA; TEL 251 115531550/251 11534777; FAX 251115514037 E-MAIL:: [email protected]

This form allows WHO to collect data from over 200 diverse countries. It is NOT a recommended data collection format for national programmes. (See WHO documents for such recommendations/guidelines: www.who.int/tb/publications/recording_and_reporting_draft).

For all questions, please indicate “NA” where the question is not applicable for your country; indicate “DK” or “Don’t know” if you do not have the information required to answer the question. Please do not leave any field blank.


Stop TB Strategy, planning and implementation

S1 Do you have a national strategic plan for TB control? Yes No

S2

S3 If yes, which of the following are specifically addressed in the plan?

1. Pursue high-quality DOTS expansion and enhancementProgramme management and supervision activities, including routine recording and reporting Yes No

Quality assured bactriology Yes No

Standardized treatment with supervision and patient support Yes No

Effective drug supply and management system Yes No

Impact measurement Yes No

Human resource development Yes No

2. Address TB/HIV, MDR-TB and other challengesCollaborative TB-HIV activities Yes No

Management of drug-resistant TB Yes No

Special populations and other high-risk groups Yes No

3. Contribute to health system strengthening

Yes No

Practical Approach to Lung Health (PAL) Yes No

4. Engage all care providersPublic-private and public-public mix (PPM) Yes No

International standards for TB care Yes No

5. Empower people with TB, and communitiesAdvocacy, communication and social mobilization Yes No

Community involvement in TB control Yes No

Patients' charter for TB care Yes No

6. Enable and promote research Yes No

Other (please specify)

S4 Did you use the WHO planning and budgeting tool to help develop your plan or a global fund proposal (round 7)? No

Please note that some of the questions ask for information for a particular fiscal year (instead of calendar year) where there is a need to make a direct link or comparison with the financial data (i.e. questions in the budget and expenditure tables). Leave/circle the correct answer

and delete the remaining ones

If yes, what time period does this plan covers (e.g., 2006–2010)?

Health systems strengthening and TB control (i.e. contributing to overall health system strengthening is explicitly mentioned as a plan objective, with defined activities)

Yes, all components

Yes, some components



S5

S6

S7 Describe the three major challenges to implementing these activities.

Describe the three major activities of the NTP in fiscal year 2006.

Describe the top three priority activities planned for fiscal year 2007.



Programme management and supervision activities, including routine recording and reportingS8 Do you have a national TB control manual (or guidelines for TB diagnosis and treatment)? Yes No

S9 If yes, what is the year of publication?S10 If yes, has it been updated to be consistent with the Stop TB Strategy? Yes No

S11 If yes, when was it updated?

S12

S13

S14 %

S15 Yes No

S16 Yes No

S17 Yes NoS18 If yes, in which of following way/s?

In the form of meetings, where there was discussion of summary indicators and comparisons between geographical areas. Yes No

In the form of written reports of summary indicators and comparisons between geographical areas. Yes No

If yes, how many times in fiscal year 2006?Other (please specify):

S19

Type of supervisory visitNTP national office to provincial/regional level (or equivalent)

Provincial/regional level (or equivalent) to district level (or equivalent)

District level (or equivalent) to health care facility

S20

DOTS units No Don't know

non-DOTS units No Don't know

How many TB basic management units (BMUs) were there in calendar year 2006?

The basic management unit is defined in terms of management, supervision, and monitoring responsibility. It may have several treatment facilities, one or more laboratories, and one or more hospitals. The defining aspect is the presence of a manager or coordinator who oversees TB control activities for the unit and who maintains a master register of all TB patients being treated, which is used to monitor the programme and report on indicators to higher levels.

How many of these BMUs were considered "DOTS" units at the end of calendar year 2006?

What proportion of the country's population was covered by basic management units defined as DOTS in calendar year 2006?If a unit became a DOTS unit in October of 2006, then use only 1/4 of its population in your calculation; if in July, then use 1/2 of its population, etc. DOTS coverage is a crude indicator of access to DOTS. The proportion of the population with access to DOTS services is lower than DOTS coverage in many countries. If you have an estimate of access to DOTS, please provide the estimate along with the definition of access and the method of estimation in "Remarks" page in addition to answering this question.

Did you use a standardized check-list for programme supervision in fiscal year 2006?

Do you have a plan for regular supervision of programme implementation for fiscal year 2007?

Was feedback on routinely collected data provided from the central office of the NTP to the first sub-national level in fiscal year 2006?

If yes, how many times in fiscal year 2006?

The number of supervisory visits planned and conducted in fiscal year 2006.Number of supervisory visits planned for 2006

Number of supervisory conducted in 2006

Was every dose of medication supervised at least during the initial phase (2-3 months) of treatment in calendar year 2006?

All patients in all units

All patients in some units

Some patients in all

units

Some patients in some units

Notapplicable




units


Notapplicable



S21 Yes No

<S22 If yes, when?

S23 Yes No

S24 Yes No if yes, please skip the next two questions.

S25 Yes No

S26 If yes, aggregated by: (for example regions, provinces, districts or health facilities)

S27

S28

S29

Data management Yes No

Data analysis Yes No

S30

Reports received by Reports sent by:

National TBL/TB and HIV Data Manager RTLCs

S31

Laboratory diagnostic servicesS32

Number of labsSmear microscopy

Culture

Drug susceptibility testing* failed to show adequate performance: one or more high false positive (HFP) or high false negative (HFN)

Have you revised your TB recording and reporting forms and registers to be in line with the WHO-recommended revised TB reporting and recording forms and registers (2006 version; http://www.who.int/tb/dots/r_and_r_forms)?

Does your TB recording and reproting system include a yearly management report (form 10, page 31-32 of the revised TB recording and reporting forms and register; http://www.who.int/entity/tb/err/rr_final_forms_en.pdf?

Did you keep (or have access to) the data for individual TB patients at the NTP central office in 2006?

Did you keep (or have access) to the aggregated TB reports (for example, the quarterly reports of provinces) at the NTP central office in 2006?

In how many TB basic management units (BMUs) were the TB data stored in a computer in 2006?

How many TB basic management units were using computer software which was distributed by the national NTP office for management of their TB data in 2006?

Were there designated persons responsible for following tasks at the central level of NTP in fiscal year 2006?

Please use this table to explain the completeness of reporting at different levels of your TB recording and reporting system for 2006 notifications and 2005 treatment outcomes (both calendar year).

Number of expected reports

Number of missing reports

Case finding, 2006

Treatment outcomes,

2005

Case finding, 2006

Treatment outcomes,

2005

If there have been any missing reports of case finding at any level, how many cases had been reported in calendar year 2005 from the units that did not report in calendar year 2006?

Please provide the number of public and non-public laboratories that worked with the NTP were subjected to external quality assurance (EQA), provided free-of-charge services and failed to show adequate performance in fiscal year 2006:

Number of labs subjected to EQA

Number of labs provided free-of-charge services

Number of labs failed to show adequate performance *



S33

S34 of total number of smear microscopy unitsS35

S36 of total number of culture unitsS37

S38 of total number of DST units

S39

S40



S41

TB diagnosis Drug susceptibility testing

All TB suspects Yes No Non-converters Yes No

Smear negative TB Yes No Re-treatment cases Yes No

Extrapulmonary TB Yes No Treatment failures Yes No

Drug resistance survey Yes No

S42

Private Yes No

NGO Yes No

University/Medical college Yes No

Yes No

Military/Police/Paramilitary Yes No

Penitentiary/prison Yes No

Other (please specify):

What percentage of TB microscopy units involved in TB control had at least one member of staff trained in AFB microscopy in fiscal year 2006?

What percentage of TB culture units involved in TB control had at least one member of staff trained in AFB culture in fiscal year 2006?

What percentage of TB DST units involved in TB control had at least one member of staff trained in AFB DST in fiscal year 2006?

In how many laboratories will you establish TB laboratory services for culture and diagnostic drug susceptibility testing (DST) in fiscal year 2007?

Was sputum microscopy routinely used to diagnose suspected pulmonary cases in calendar year 2006? In DOTS units:




units


Notapplicable




units


Notapplicable

What was your country's policy for culture (i.e. for which patients did you systematically perform culture) in fiscal year 2006?

Other (please specify): Other (please specify):

Please indicate if you collaborated with non-NTP laboratories in any of the following sectors in fiscal year 2006.

Services provided through private or social insurance schemes



S43

For microscopy:

For culture:

For DST:

S44

Laboratory reagents and supplyCentral level Yes No

Peripheral levels All units Some units No don't know

S45 If yes, describe the stock-out situation and steps taken to solve the problem and specify if diagnosis was delayed as a result.

S46 Do you have national guidelines for laboratory supervision? Yes No

S47 If yes, what is the year of publication?

S48 Yes No

S49

S50

If there was no EQA system in 2006, what are the plans for implementation of EQA in fiscal year 2007?

Were there any stock-outs of laboratory reagents and supplies at any level in fiscal year 2006?

Did you have a national reference laboratory or laboratories (NRL) in fiscal year 2006?

Please describe the three major activities related to the laboratory services in fiscal year 2006.

Please describe the top three priority activities related to the laboratory services planned for fiscal year 2007 (including, if any, additional TB laboratory services for culture and diagnostic drug susceptibility testing)



Human Resource DevelopmentS51 Have you completed a human resource development (HRD) needs assessment? Yes No

S52 Do you have a comprehensive strategic HRD plan for TB control? Yes No

S53 If yes, what time period does the plan cover?

S54 Training needs Staffing needsDOTS expansion and enhancement? Yes No Yes No

Management of MDR-TB? Yes No Yes No

Management for collaborative TB/HIV activities? Yes No Yes No

Implementation of Public-Private and public-public Mix strategies? Yes No Yes No

S55 Are job descriptions up-to-date (i.e. do they correspond with the current policies and recommendations for TB control)? All up-to-date

S56 Is TB control (following NTP guidelines) formally included in the curricula for basic training of the following categories of health worker?

Doctors Yes No

Nurses Yes No

Laboratories technicians Yes No


S57 Have teaching staff in the respective basic training institutions been trained on the content of the Stop TB strategy?

Teaching staff in medical schools Yes No

Teaching staff in nursing schools Yes No

Yes No

S58

S59 Total number of health care units

S60 Yes No

S61 If yes, what percentage of this person's time was given for HRD-related activities? %

S62

Provincial/state Yes No

District/sub-district Yes No

Health facilities Yes No

If yes, which of the following are included in the plan?

Almost all up-to-date

Some up-to-date

None up-to-date

Teaching staff in training institutions for laboratories techniciansOther (please specify):

What percentage of health care units had at least one healthcare professional trained in TB control based on the Stop TB Strategy in fiscal year 2006?

Was there a designated person at the central level of the NTP responsible for HRD activities for TB control in fiscal year 2006?

At which level(s) of the health system were there full-time staff dedicated to TB control in fiscal year 2006?



S63 For countries with dedicated TB control staff, fiscal year 2006

National Level

Provincial/Regional Level

District Level

Health Care Unit Level

Laboratories

Other (specify)

Other (specify)

Drug management

S64



S65



S66

First-line TB drugs

Central level Yes No Yes No

All units Some units No All units Some units No

S67 If yes, describe the drug stock-out situation and steps taken to solve the problem and specify if treatment was delayed or interrupted as a result.

How many posts were there in the NTP to

perform TB control tasks in 2006?

How many of these posts were filled in 2006?

Of those posts filled, how many of these staff were trained in TB control in

2006?

Was standardized, short-course chemotherapy (less than 9 months) used routinely to treat TB patients in categories I, II and III (i.e., all patients except chronic and proven or suspected MDR-TB patients) in calendar year 2006? If there is any category for which standardized short-course chemotherapy is not used, please specify in "Remarks". For WHO-recommendations, see www.who.int/entity/tb/publications/tb_2003_313_chap4_rev.pdf)




units


Notapplicable




units


Notapplicable

Were TB drugs provided free-of-charge to all TB patients treated with first-line drugs under the NTP in calendar year 2006?




units


Notapplicable




units


Notapplicable

Were there any stock-outs of TB drugs at any level in fiscal year 2006? Stock-out is defined as the number of days that a product was not present in the storage facility over a recent 12-month period (usually the 12 months preceding the time of questionnaire completion). To be considered a stock-out, there must have been none of an unexpired drug unit in stock. If even small quantities of an unexpired drug unit were present, the drug unit should be counted as in stock.

Second-line drug stock-outs in MDR-TB management units

Peripheral levels which resulted in treatment interruption or delay in start of treatment for TB patients



S68 What is/are the NTP-recommended regimen/s for TB treatment?

Category I

Category II

Category III (if any)

Children (if any)

S69 If the recommended category I treatment regimen does not include rifampicin in the continuation phase, do you intend to introduce it? Yes No Not applicable

S70 If so, when?

S71 Yes No

S72 Yes No

S73 Was your country using FDCs in fiscal year 2006? Yes No

S74 Yes, with FDC drugs Yes, without FDC drugs No

S75 Yes No

S76 Yes No

S77

Capreomycin Yes No Ethionamide Yes No Ofloxacin Yes No Prothionamide Yes No

Cycloserin Yes No Kanamycin Yes No PASER Yes No Other

S78 Yes No

S79

S80 Yes No

S81 Yes No Partially

S82 Please specify:

S83 Did you provide free anti-TB drugs to the collaborating non-NTP providers in fiscal year 2006? Yes No

S84

Use "H" for isoniazid, "R" for rifampicin, "Z" for pyrazinamide, "S" for streptomycin, "E" for ethambutol. Use "/" to distinguish the initial phase from the continuation phase. A number before a phase indicates the duration of that phase in months. Parentheses "()" indicate fixed-dose combinations. A number after a letter or letters in parentheses indicates the number of doses per week; no numbers indicates that the treatment is daily or 6 times weekly. Example: 2(HRZE)/4(HR)3: initial phase 2 months, daily treatment with isoniazid, rifampicin, pyrazinamid and ethambutol in fixed-dose combination; continuation phase 4 months with isoniazid and rifampicin in fixed-dose combination 3 times per week.

Were first-line TB drugs available outside the NTP in fiscal year 2006?

Were second-line TB drugs available outside the NTP in fiscal year 2006?

Was your country using patient kits in fiscal year 2006?

Was quality control a routine part of drug management activities in fiscal year 2006? (i.e. prior to customs clearance and/or after distribution within the country)

Were second-line drugs used within the NTP in fiscal year 2006?

If yes, which of the following second-line drugs were used by the NTP in fiscal year 2006.

If your answer to the question S76 is yes, were the second-line drugs provided through the GLC mechanism in fiscal year 2006?

If your answer to the question S76 is yes, what was the source of second-line drugs (e.g. GDF, local manufacturer, foreign manufacturer) in fiscal year 2006?

Were anti-TB drugs procured specifically for use in children in fiscal year 2006?

Were TB drug procurement, distribution and stock management systems performed together with other essential drugs management systems in fiscal year 2006?

Describe the top three priority activities related to drug management planned for fiscal year 2007.



Impact measurementS85 Do you publish an annual report of the activities of the NTP? Yes No

S86 If yes, in which year did you start publishing annual reports?

S87 Do you have a plan to assess the impact of TB control on the burden of TB in your country? Yes No

S88

In-depth analysis of routine surveillance data Yes No If yes, in which year:

Population-based prevalence of disease survey Yes, national survey Yes, sub-national survey No If yes, in which year:

Population-based prevalence of infection survey Yes, national survey Yes, sub-national survey No If yes, in which year:

Population-based mortality survey (e.g. verbal autopsy study) Yes No If yes, in which year:

Analysis of vital registration mortality data Yes No If yes, in which year:


Collaborative TB-HIV ActivitiesS89 Yes No

S90 Yes No

S91 Yes, to all patients Yes, for specific groups No policy

S92 If yes, is this policy for provider-initiated testing. Yes No

S93 Yes No

S94 If yes, what sources of data were used:Data from the routine HIV testing of TB patients? Yes No

Data from sentinel site surveys? Yes No

Other, please specify

S95 Yes No

S96 Yes No

S97 Yes No

S98 Yes In some settings only No

S99 Yes In some settings only No

S100 Yes No

S101

ART drugs (Antiretroviral therapy) Yes No

Co-trimoxazole preventive therapy (CPT) Yes No

Training Yes No

HIV testing Yes No

IPT Yes No


If yes, how do you plan to assess the impact of TB control on the burden of TB in your country in the next 10 years?

Was there a designated person at the central level of the NTP responsible for coordinating TB/HIV activities in fiscal year 2006?

Was there a designated person at the national HIV programme responsible for coordinating TB/HIV activities in fiscal year 2006?

Was there a national policy to offer HIV counselling and testing to all TB patients in calendar year 2006?

Was there a national surveillance system to measure the prevalence of HIV in TB patients, in calendar year 2006?

Was there a national body responsible for coordinating TB/HIV activities in fiscal year 2006?

Was there a national plan for collaborative TB/HIV activities in fiscal year 2006?

Was there a national policy to offer isoniazid prophylaxis (treatment of latent TB infection) to people with HIV in calendar year 2006?

Was there a national policy to offer co-trimoxazole preventive therapy (CPT) to HIV-positive TB patients in calendar year 2006?

Was there a national policy to offer antiretroviral therapy (ART) to HIV-positive TB patients in calendar year 2006?

Was there a national policy to screen people living with HIV for TB in 2006?

Which of the following components of collaborative TB/HIV activities were paid for from the NTP budget in fiscal year 2006?



S102

Hospitals Yes No

Clinics Yes No

Military barracks Yes No

Prisons Yes No

S103 Yes No

S104

S105

Management of drug-resistant TB

S106

Yes No If yes, when

Drug resistance survey conducted Yes No If yes, when

Application to the GLC submitted Yes No If yes, when

GLC-approved projects piloted Yes No If yes, when

National drug-resistant TB guidelines developed Yes No If yes, when

Training material developed Yes No If yes, when

Training specifically for drug resistant TB conducted Yes No If yes, when

Scaling-up phase initiated Yes No If yes, when

Drug-resistant TB activities fully integrated in NTP Yes No If yes, when


Did you have a policy for controlling the spread of TB in the following congregate settings in calendar year 2006?

Do you plan to analyze the outcome of the 2006 cohort of TB patients by HIV status?

Describe the three major activities in addressing TB-HIV in fiscal year 2006.

Describe the top three priority activities planned to address TB-HIV in fiscal year 2007.

Notes: MDR = multidrug-resistant. DST = drug susceptibility testing. GLC = The Green Light Committee: The mechanism of WHO and its partners of the Stop TB Partnership to enable access to second-line anti-TB drugs in low- and middle-income countries to treat multidrug-resistant tuberculosis (MDR-TB) under programmatic conditions and following specific guidelines. For further information, see http://whqlibdoc.who.int/publications/2006/9241546956_eng.pdf

What is the status of management of drug-resistant TB in your country?

A person at the central level of the NTP responsible for drug resistant TB designated



S107 Yes No

S108

S109

Special Populations and Other High-Risk GroupsS110 If the NTP has specific plans for TB control in the special populations and other high-risk groups, does the plan include the following?

Prison populations Yes No

Refugees/displaced people Yes No

Migratory workers Yes No

Immigrants Yes No

Cross-border populations Yes No

Orphaned/homeless Yes No

Slum dwellers Yes No

Ethnic minorities Yes No

Alcohol abusers Yes No

Injecting drug users Yes No

People with diabetes Yes No

People who smoke tobacco Yes No


S111 If yes, please provide a brief description of the plans:

If management of drug-resistant TB is part of the activities of the NTP, does it follow WHO guidelines for the programmatic management of drug-resistant tuberculosis? (http://whqlibdoc.who.int/publications/2006/9241546956_eng.pdf)

Notapplicable

Describe the three major activities implemented to address drug-resistant TB in fiscal year 2006.

Describe the top three priority activities planned to address drug-resistant TB in fiscal year 2007.



S112

Population movement due to political unrest Yes No If yes, please specify

Population movement due to war Yes No If yes, please specify

Population movement due to natural disaster Yes No If yes, please specify

S113

Provision of incentives (e.g. foods) Yes No

Enablers (e.g. free transport) Yes No

Setting up additional service points Yes No

Adjusting clinic hours Yes No


S114 Yes No

S115

In children under 5 years of age who have been close contacts of people with smear-positive pulmonary TB Yes No

In people living with HIV/AIDS who have been close contacts of people with smear-positive pulmonary TB Yes No


Health Systems Strengthening and TB ControlS116 Apart from the NTP, which national partners have taken part in the planning of TB control?

MoH planning department Yes No

Hospital administration department or equivalent Yes No

Ministry of Education (e.g. medical colleges) Yes No

Ministry of Interior/ Justice (prisons) Yes No

Ministry of Defence (army health facilities) Yes No

Other Ministries (please specify)

Drug regulatory body Yes No

National health insurance office Yes No

HIV programme Yes No

Other disease programmes Yes No

NGOs Yes No

Professional associations Yes No

Other

Was the NTP addressing TB control in any of the following special situations in fiscal year 2006?

Did the NTP have any specific initiatives for the following in fiscal year 2006?

Did the NTP have any specific initiatives to address gender-related issues (e.g. staff training on gender, links with women's groups, etc) in fiscal year 2006?

Did you have a national policy to investigate the close contacts of smear-positive pulmonary TB cases for latest infection with Mycobactrium TB and for active TB in the following groups in 2006:



S117 Which of the following exist in the country?

Plan for national human resource for health Yes No don't know Not applicable

If yes, is the NTP plan and budget aligned (i.e. linked to and coordinated) with it? Yes No don't know Not applicable

Plan for national health development Yes No don't know Not applicable


Poverty Reduction Strategy Paper Yes No don't know Not applicable


Medium-term Expenditure Frameworks for health Yes No don't know Not applicable


Sector Wide Approach (SWAp) Yes No don't know Not applicable


S118 Yes Partially NoS119 Please specify

S120

S121

Practical Approach to Lung Health (PAL)S122

Not yet implemented Yes No

National working group on PAL established Yes No

Pilot phase Yes No

Guidelines developed Yes No

Scaling up Yes No

Implemented throughout the country Yes No


Were NTP laboratory services for TB diagnosis integrated into general laboratories in fiscal year 2006?

Describe the three major activities of the NTP in contributing to overall health system strengthening beyond TB control activities in fiscal year 2006.

Describe the top three priority activities planned to contribute to health system strengthening beyond TB control activities in fiscal year 2007.

What is the current status of PAL (Practical Approach to Lung Health) in your country?



Public-Private and Public-Public Mix (PPM) [including International Standards for TB Care (ISTC)]S123 Yes No

S124 If yes, what percentage of this person's time was given for PPM-related activities? %

S125 Do you have guidelines on TB management for medical practitioners working outside public health clinics? Yes No

S126 If yes, what is the year of publication?S127 Yes No

S128 What was the current status of PPM-related activities in your country?

Situational analysis Yes No

Guidelines development Yes No

Training material development Yes No

Pilot projects Yes No

Scaling up Yes No


S129

Refer (to NTP facilities) Treat (with programme drugs)

Private practitioners All Some No All Some No All Some No

Private hospitals All Some No All Some No All Some No

NGO/mission clinics & hospitals All Some No All Some No All Some No

Corporate (business) health services All Some No All Some No All Some No


S130

Refer (to NTP facilities) Treat (with programme drugs)

General public hospitals All Some No All Some No All Some No

Medical college hospitals All Some No All Some No All Some No

Health/social insurance services All Some No All Some No All Some No

Prison All Some No All Some No All Some No

Military All Some No All Some No All Some No


S131

S132 Yes No

Was there a designated person at the central level of the NTP responsible for activities related to involving non-NTP providers in TB control in fiscal year 2006?

Did the NTP conduct training specifically for non-NTP health-care providers in fiscal year 2006?

Did the following private sector providers in your country collaborate with the NTP for DOTS implementation in fiscal year 2006?

Diagnose (according to programme guidelines)

Did the following public sector providers in your country collaborate with the NTP for DOTS implementation in fiscal year 2006?

Diagnose (according to programme guidelines)

How many of the Basic Management Units (BMUs) had formal PPM activities in place in calendar year 2006?

Was the referral source (by different public and private providers) routinely recorded in the laboratory register, as suggested in the WHO revised recording and reporting guidelines in calendar year 2006?



S133

S134

S135 Yes No

S136 Have ISTC been formally endorsed by any professional association(s) in the country? Yes No

S137 If yes, which association(s)?

Advocacy, Communication and Social Mobilization (ACSM)

S139 If the NTP plan includes ACSM activities, please identify which of the following target groups are covered in your national ACSM plan. If not, skip this question.

General public (e.g. through encouraging care seeking behaviour, educating on symptoms of TB, combating stigma etc.) Yes No

TB suspects and patients (e.g. through educating on where to go for TB testing and treatment Yes No

Health care providers (eg. through provider targeted information Yes No

Policy makers and planners (e.g. through calling for increased political & financial support Yes No

S140 Have indicators been developed to measure the impact of ACSM activities in your country? Yes No not applicable

S141 Identify the areas of technical assistance that would help improve your ACSM activities?

Establishing surveys and baseline data (to help identify target audiences and to determine behaviour change targets) Yes No

Development of messages and targeted materials Yes No

Update of the ACSM strategy and the rollout of activities Yes No

Project management training for ACSM activities at all levels Yes No

Monitoring and evaluation of ACSM activities Yes No

S142

S143 Yes No

S144 Have you conducted a Knowledge, Attitudes and Practices (KAP) or similar survey on TB? Yes No

S145 If yes, in which year:

Describe the three major activities related to PPM in fiscal year 2006.

Describe the top three priority activities planned related to PPM in fiscal year 2007.

Were you using ISTC to promote involvement of non-NTP providers in TB control in fiscal year 2006?

Advocacy, Communication and Social Mobilization (ACSM) is a term that describes a set of activities aimed at encouraging care seeking behaviour, educating on signs and symptoms of TB, educating on where to go for TB testing and treatment, increasing knowledge of risk factors for TB, combating stigma, providing a channel for afflicted individuals and communities to voice needs and concerns, encouraging community action, calling for increased political and financial support for local, national and international action.

How many Basic Management Units (BMUs) implemented ACSM activities in fiscal year 2006?

Were patient-centred organizations or networks (with cured TB patients as members) involved in TB advocacy activities and/or DOTS implementation in calendar year 2006?



S146

S147

Community involvement in TB controlS148 Yes No

S149

S150

S151

Describe the three major activities related to ACSM in fiscal year 2006.

Describe the top three priority activities related to ACSM planned for fiscal year 2007.

Was community involvement in TB control (e.g. referral of suspects, patient support) implemented in fiscal year 2006? (http://whqlibdoc.who.int/hq/2003/WHO_CDS_TB_2003.313.pdf)

If yes, how many BMUs involved communities in TB control in fiscal year 2006?

Describe the three major activities related to community involvement in TB control in fiscal year 2006.

Describe the top three priority activities related to community involvement in TB control planned in fiscal year 2007.



Patients' Charter for TB CareS152 Yes No

S153 If yes, how many copies were distributed?

S154

Operational Research S155

S156 Please list the name of each project.

S157

Was the Patients' Charter or other code of conduct disseminated in fiscal year 2006?

Describe the three major activities related to promoting pateints' charter for TB care planned in fiscal year 2007.

How many operational research projects were initiated in collaboration with the NTP in the country in fiscal year 2006? Operational research: research specifically aimed at developing interventions that result in improved policy-making, better design and implementation of health systems, and more efficient methods of service delivery.

Please list the name of each operational research project planned for fiscal year 2007?



PartnershipS158

. Name of agency Area of work

S159

Name of agency Area of work

S160

Name of agency Area of work

S161 Please describe the TB coordination mechanism at country level, if any (e.g. Stop TB Partnership, Interagency coordination mechanism, , etc).

The Global Fund to Fight AIDS, TB and MalariaS162 Briefly describe any challenges you face in accessing and/or using Global Fund financing. Please specify the round and the phase for which there are challenges.

List the international technical and financial partners that supported TB control in your country in fiscal year 2006? Note that a technical partner could also provide financial support.

List the local/national technical and financial partners that supported TB control in your country in fiscal year 2006.

List the local/national or international technical TB partner(s) that is/are the focal partner(s) in your country for TBTEAM (TB Technical Assistance Mechanism).



DOTS Non-DOTSStrategy applies to basic management units, not individual patients. If a unit is a "DOTS" unit, then all cases from that unit should be reported as DOTS cases.

N1 New pulmonary smear-positive

N2 New pulmonary smear-negative

N3 New pulmonary smear-unknown/not done

N4 New extrapulmonary

N5 Other NEW cases not in lines N1–N4

N6

N7

N8

N9

N10

0 0

N11

N12 Total number of TB cases in 2006

N13

N14

N15

TB notifications, 2006 calendar year (number of patients)

Number of these cases, by strategy, that are

Relapse (smear-positive pulmonary)

Treatment after failure (smear-positive pulmonary)Treatment after default (smear-positive pulmonary)Other RE-TREATMENT cases not in lines N6–N8.

Other, not in lines N1-N9 (i.e., history unknown). Please specify what these cases are, in "Remarks."

New pulmonary lab-confirmed cases Lab-confirmed includes smear-positive cases plus any cases confirmed by additional laboratory methods.

Out of all new smear-positive cases notified in 2006, how many were referred or diagnosed by non-NTP providers?

How many people with symptoms and signs suggestive of TB (e.g. cough of long duration; more than 2-3 weeks) were screened for TB in 2006?

Number of TB deaths registered by the vital registration system of your country following the ICD-10 codes for TB in 2006?



DOTS0-4 5-14 0-14 15–24 25–34 35–44 45–54 55–64 65+

N16 Male

N17 Female

Non-DOTS

N18 Male

N19 Female

DOTS0-4 5-14 0-14 15–24 25–34 35–44 45–54 55–64 65+

N20 Male

N21 Female

Non-DOTS

N22 Male

N23 Female

DOTS0-4 5-14 0-14 15–24 25–34 35–44 45–54 55–64 65+

N24 Male

N25 Female

Non-DOTS

N26 Male

N27 Female

New pulmonary smear-positive TB cases, 2006 calendar year (number of patients)

Red colour indicates that the age-sex total is not equal to the number of notified cases. Please re-check the numbers and explain any discrepency in "Remarks". If you have data by age and sex that do not fit this framework (e.g., different age groups), then you can provide the data that you have in “Remarks”.

Total (calculated

automatically)

New pulmonary smear-negative/smear-unknown/smear-not done TB cases, 2006 calendar year (number of patients)Total

(calculated automatically)

New extrapulmonary TB cases, 2006 calendar year (number of patients)Total




Other

N28

N29

N30

N31

N32

N33

N34

N35 How many of these patients (question N34) were identified as MDR-TB based on DST in 2006?

TB-HIV, 2005 and 2006 calendar year

2005 2006

N36

N37 Of these (i.e. question N36), how many were recorded to be HIV positive?

N38 Yes No

N39

N40

N41

N42

N43 Of these, how many were diagnosed with TB during 2006?

N44

N45

N46 What is the national estimate of the prevalence of HIV in TB patients?

N47 To which year does the estimate of HIV prevalence in TB patients belongs to?

N48

MDR-TB, 2006 calendar year (number of patients)GLC-

approved

How many new and re-treatment patients received diagnostic drug susceptibility testing (DST) in 2006?

Among those new and retreatment patients tested (question N28), how many laboratory-confirmed cases of MDR-TB were identified?

How many patients registered as new cases received diagnostic DST in 2006?

Among those new patients tested (question N30), how many laboratory-confirmed cases of MDR-TB were identified in 2006?

How many patients registered as re-treatment cases received diagnostic DST in 2006?

Among those retreatement patients tested (question N32), how many laboratory-confirmed casesof MDR-TB were identified in 2006?

How many treatment after failure patients (or patients at point of failure) received diagnostic DST in 2006? Please note that these patients are a subset of patients in question N32.

Notes: MDR = multidrug-resistant. DST = drug sensitivity testing. GLC = The Green Light Committee: The mechanism of WHO and its partners of the Stop TB Partnership to enable access to second-line anti-TB drugs in low- and middle-income countries to treat multidrug-resistant tuberculosis (MDR-TB) under programmatic conditions and following specific guidelines. For further information, see www.who.int/tb/dots/dotsplus/management/en

Data on cotrimoxazole preventive therapy and antiretroviral therapy should be reported with the quarterly data on TB treatment outcomes and therefore final numbers for 2006 may not be available yet. However we request that you provide us with provisional numbers for 2006 as well as the final numbers for 2005.

How many TB patients had an HIV test result recorded in the TB register in 2005 and 2006? This should include those TB cases that were previously known as HIV-positive or their negative HIV result from previous testing was acceptable to the clinician (e.g. done in the last 3-6 months in a reliable laboratory)

Do the numbers reported in questions N36 and N37 include those TB cases that were previously known as HIV-positive or their negative HIV result from previous testing was acceptable to the clinician (e.g. done in the last 3-6 months in a reliable laboratory)?

How many HIV-positive TB patients (i.e. question N37) started or continued on co-trimoxazole preventive therapy in 2005 and 2006?

How many HIV-positive TB patients (i.e. question N37) started or continued on ART in 2005 and 2006?

How many people in your country were known to have HIV in 2006? (include everyone in the HIV care or ART register, regardless of year of diagnosis)? If you do not have such registers, provide the number of people newly diagnosed with HIV in 2006 and make a note of this in "Remarks".

Of these, how many were screened for TB at least once during 2006?

Of these, how many were on ART registers during 2006?

How many people living with HIV were given isoniazid prophylaxis (treatment of latent TB infection) in 2006?

Please provide a reference to the source of the estimate (if it is available electronically, please attach it or provide a web address) or describe the survey design including population studied, sampling method and sample size.



N49 Culture Smear or culture Not applicable

DOTS Cured Completed Died Failed Defaulted


N51


N53

N54

N55

N56 Other re-treatment

non-DOTSN57 New pulmonary smear-positive

N58


N60

N61

N62


Treatment outcomes for cases registered in calendar year 2005 (number of patients)If treatment outcomes for re-treatment cases cannot be separated into relapse, after-failure and after-default, then please provide these outcomes in row "Other re-treatment" and mention in "Remarks" which types of re-treatment cases contributed in this row.

If you are not able to report the treatment outcomes of pulmonary cases only by smear status, please specify that the reported cases have been confimred by which of the following methods:

Red colour indicates that the number of evaluated cases is not equal to the number of registered cases. Or, the number of cases registered for treatment is different from what was previously notified. Please re-check the numbers and explain any discrepancy in "Remarks".

Total number of cases

registered Transferred

out*

Total evaluated


New pulmonary smear-negative/unknown/not done


Treatment after failure (smear-positive pulmonary)

Treatment after default (smear-positive pulmonary)







Cured Completed Died Failed Defaulted


N65


N67

N68

N69


N71 All TB cases

GLC-approved Cured Completed Died Failed Defaulted

N72 New cases

N73 Re-treatment cases

N74 Other cases

Other

N75 New

N76 Re-treatment

N77 Other

* "Transferred-out" means transferred out and not evaluated. It is the subset of transfer patients for whom the outcome was not evaluated.

Treatment outcomes for HIV-positive TB cases registered in calendar year 2005 (number of patients)

If treatment outcomes for HIV-positive cases cannot be separated into different case types (questions N62-N68), then please provide these outcomes in N69 (All TB cases) and mention in "Remarks" which types of cases contributed in this row.



out*

Total evaluated



Relapses (smear-positive pulmonary)



Final treatment outcomes for MDR cases registered in 2003 (number of patients)



out*

Total evaluated




Financial informationBUDGET

F1 Beginning of your fiscal year 2007 (day/month/year)

F2 Expected number of new smear-positive patients to be treated in 2007GLC-approved Other

F3 F5 How many MDR-TB patients are expected to be treated in 2007?

EXPECTED Funding

BUDGET LINE ITEMS: Calculated gap

F6 First-line TB drugs

F7 Staff working for TB control (central unit staff and subnational TB staff)

F8 Routine programme management and supervision activities

F9 Laboratory supplies and equipment for smears, culture and DST

F10 PAL (Practical Approach to Lung Health)

F11 PPM (Public-Public, Public–Private Mix-DOTS)

F12 Collaborative TB/HIV activities

F13 Second-line drugs for MDR-TB

F14 Management of MDR-TB (budget excluding second-line drugs)

F15 Community involvement

F16 ACSM (Advocacy, communication and social mobilization)

F17 Operational research

F18 Surveys to measure TB burden and impact of TB control

F19 All other budget lines for TB (e.g., technical assistance)

F20 TOTAL

0 0 0 0 0 0

Please see sheet "Instructions" to complete this section

FISCAL YEAR 2007F4 How many HIV-positive TB patients are expected to start ART in 2007?

Expected number of new smear-negative/extra-pulmonary patients to be treated in 2007

Please report the financial data in ABSOLUTE US Dollars

BUDGET REQUIREDa Governmentb Loansc Global Fundd Other GrantseGAPf



F21 Beginning of your fiscal year 2008 (day/month/year)

F22 Expected number of new smear-positive patients to be treated in 2008GLC-approved Other

F23 F25 How many MDR-TB patients are expected to be treated in 2008?

EXPECTED Funding

BUDGET LINE ITEMS: Calculated gap

F26 TB drugs of first-line














F40 TOTAL

0 0 0 0 0 0 0

FISCAL YEAR 2008 Red colour indicates that the numbers in that row or column do not add up to the total you have entered. Please double-check and provide an explanation in "Remarks" if necessary.

F24 How many HIV-positive TB patients are expected to start ART in 2008?

Expected number of new smear-negative/extra-pulmonary patients to be treated in 2008

Please report the financial data in ABSOLUTE US Dollars

BUDGET REQUIREDa Governmentb Loansc Global Fundd Other GrantseGAPf



Utilization of health servicesF41

%

F42 F45 Estimated average duration of stay for new smear-positive patients if hospitalized (days)

F43 Estimated percentage of new smear-positive patients that are hospitalized

EXPENDITURERed colour indicates that your numbers do not add up to calculated totals. Please re-check.

RECEIVED Funding

F48 TB drugs of first-line














F62 TOTAL

Please contact the following people for assistance if required: Rafel Lopez Olarte, [email protected] (for AMR); Katherine Floyd, [email protected] (for EUR, SEAR, WPR); Andrea Pantoja, [email protected] (for AFR, EMR).

Typical number of visits to a health facility required for one new smear-positive patient after diagnosis is made F44 Estimated percentage of new smear negative/extra-pulmonary patients that are hospitalized

Typical number of visits to a health facility required for a new smear negative/extra-pulmonary patient after diagnosis is made

%F46 Estimated average duration of stay for new smear negative/extra-pulmonary patients if hospitalized (days)

F47 Number of hospital beds used exclusively for TB (including beds in sanatoria, where these exist)

FISCAL YEAR 2006Please report the financial data in ABSOLUTE US Dollars

ACTUAL EXPENDITUREg Governmenth Loansi Global Fundj Other Grantsk


Instructions for pages F_inance (financial information)

Budget items

F1 & F21 The date of the beginning of your fiscal year (between 1 January and 31 December of the year indicated)

F2 & F22 The number of patients you expect to detect and treat -- new smear-positive cases in all areas (DOTS and non-DOTS). It does NOT mean the total estimated incident number of cases in your country.

F3 & F23 The number of patients that you expect to detect and treat -- new smear-negative and extra-pulmonary cases in all areas (DOTS and non-DOTS). It does NOT mean the total estimated incident number of cases in your country.

F4 & F24 The number of HIV+TB patients that you expect will start ART treatment in this year, either in the NTP programme or in the National AIDS programme. If patients are provided ART by the National AIDS programme please let us know it in the remarks.

F5 & F25

F6 & F26

F7 & F27

F8 & F28

F9 & F29 Budget for laboratory supplies and equipment for microscopy, culture and DST, including for external quality assurance.

F10 & F30 Budget necessary to manage PAL, including training sessions (if different from general training), meetings, staff (not already included in number F7&F27) and development of guidelines.

F11 & F31 Budget necessary to manage PPM, including training sessions (if different from general training), meetings, staff (not already included in number F7&F27), development of guidelines and any paying scheme that might exist.

F12 & F32

F13 & F33 Budget for second-line drugs, include drugs procured through the Green Light Committee (GLC) and through other mechanisms.

F14 & F34 Budget for the management of MDR-TB (excluding anti-TB drugs for MDR-TB). Include all the activities/staff related to programme management, such as staff (not already included in F7&F27), training or DRS.

F15 & F35 Budget for activities related community involvement, including policy development, training (if not included already in F8&F28), incentives and enablers.

F16 & F36 Budget for activities related to advocacy, communication & social mobilization, and community-based care, including workshops to create awareness, mass media campaigns or World TB Day.

F17 & F37 Budget for operational research. Please remember, that OR studies are designed to answer specific questions arising from routine data and management such as "Why do we have a high default rate".

F18 & F38 Budget for periodic surveys to measure burden of TB and impact of TB control, e.g. disease prevalence surveys, ARI surveys, surveys of TB mortality.F19 & F39 Include in the "Other" category all other budget lines not included in previous budget lines. Possible examples are technical assistance, supplies and equipment for X-rays.

Utilization of health services

F41

F42

F43

F44 The approximate percentage of smear-negative or extrapulmonary patients hospitalized for TB treatment (for any duration of stay), in view of your treatment guidelines. If unsure, please give a range.

F45 If a smear-positive patient is hospitalized for TB treatment, the average number of days they would spend in hospital.

F46 If a smear-negative or extrapulmonary patient is hospitalized for TB treatment, the average number of days they would spend in hospital.

F47 Estimated number of beds in TB hospitals and in TB wards of other hospitals. Include sanatoria beds if these exist.

Expenditure items

F48 Report actual expenditures on item, see explanation for item F6 above, and the funds received for the same line item.














Sources of funding

a The total budget required should be in line with your annual plan of activity. Indicate the total amount required to carry out all activities and NOT only the amount you expect to receive.

b Include funding from both the central and peripheral government sources (provinces, districts, etc.).

c All loans for TB or amount for TB in an overall health sector-wide loan.

d Grants awarded by the Global Fund to Fight AIDS, Tuberculosis and Malaria (Global Fund). The amount for the relevant fiscal year only and NOT the total amount of the grant.

e All grants, excluding Global Fund grants. The amount should be for the relevant fiscal year and not the total amount of the grant.

f The amount in this column should equal the "Total budget required" column MINUS the total of all expected funding columns (i.e. government, loans, grants excluding Global Fund, Global Fund grants, other).

g Report the amounts that were actually spent on each line item during your last fiscal year. The total in this column might not be equal to h+i+j+k when actual expenditures are different to the amount of funds received.

h+i+j+k Report the funds actually received from each source of funding. The total amount from all sources might be higher than the expenditure reported, but not lower.

Please remember that funding for TB control can only be improved if some attempt to describe the financial situation is made, even if data availability is limited. If the central NTP office has no information on the exact amounts that peripheral governments make available for TB control, please try to estimate.

For all questions, please indicate “NA” or “not applicable” if the intervention asked for (e.g., hospitalization) is not used in your country, and indicate “DK” or “Don’t know” if you do not have the information required to answer the question. Please do not leave any field blank.

The number of MDR-TB patients that you expect to treat. Please report separately: a) GLC-approved, which means the number of patients that are treated in your country according to international standards in the given year, i.e. that are under a GLC project; and b) Other, which means the number of patients treated in your country under other types of treatment.

Budget for anti-TB drugs, excluding drugs to treat multidrug-resistant (MDR) TB. If drugs are provided by the Global Drug Facility (GDF), please include an estimate of the value of these drugs. Please include the budget for all first-line drugs used to treat category I, II and III cases, i.e. all new (including children) and retreatment cases, and the budget for buffer stock (if any).

Staff cost for staff working ONLY on TB activities at central and peripheral levels (for example provincial TB coordinators, district TB coordinators, etc). Do NOT include, for example, primary health care nurses working on several diseases, including TB.

Budget for activities to manage and supervise the TB control programme. Possible examples are training, policy development, meetings, visits for supervision, fuel for supervision, purchase of office equipment/vehicles, construction of buildings for use by staff programme, recording and reporting, and drug management.

Activities involving collaboration between TB and HIV programmes aimed at reducing the impact of HIV-related TB. These include TB/HIV coordinating bodies, joint TB/HIV training and planning, HIV testing for TB patients, HIV surveillance among TB patients, TB screening for people living with HIV/AIDS, isoniazid preventive therapy, joint TB/HIV information/education/communication, antiretroviral treatment for TB patients, etc. Does NOT include staff dedicated to TB and partially managing TB/HIV activities already accounted for F7&F27. For clarifications, please see the WHO TB/HIV interim policy or the Monitoring and Evaluation guide.

The average number of visits per smear-positive patient to any health facility during TB treatment, for example for observed treatment (DOT), collection of drugs, smear monitoring, etc. after the patient has been diagnosed with TB, in view of your treatment guidelines. For example, if directly observed treatment is provided daily in the intensive phase at clinics and, in the continuation phase 4 visits are required (one per month for collection of drugs), the total would be 60+4=64

The average number of visits per smear-negative and extra-pulmonary TB patient to any health facility during TB treatment, for example for DOT, collection of drugs, smear monitoring, etc. after the patient has been diagnosed with TB, in view of your treatment guidelines.

The approximate percentage of smear-positive patients hospitalized for TB treatment (for any duration of stay), in view of your treatment guidelines. For example, if your policy or general practice is to admit all TB patients for 2 months, the figure will be 100%. If unsure, please give a range.


Remarks

Thank you for completing the WHO annual data collection form. Please return it to your local/regional WHO office.

Ethiopia

DOTS Coverage - TB notificationsDOTS Total TB cases notified, DOTS TB cases notified, non-DOTS

coverage notified cases New pulmonary New extra- Other Re-treatment cases New pulm. New pulmonary New extra- Other Re-treatment cases New pulm.

Year % new & relapse ss+ ss- sm unk. pulmonary new Relapse After failure After default Other re-treat. Other lab. confirm. ss+ ss- sm unk. pulmonary new Relapse After failure After default Other re-treat. Other lab. confirm.

Ethiopia19801980 40,096

Ethiopia19811981 42,423

Ethiopia19821982 52,403

Ethiopia19831983 56,824

Ethiopia19841984 65,045

Ethiopia19851985 71,731

Ethiopia19861986 80,846

Ethiopia19871987 85,867

Ethiopia19881988 95,521

Ethiopia19891989 80,795

Ethiopia19901990 88,634

Ethiopia19911991 60,006

Ethiopia19921992 60,006

Ethiopia19931993

Ethiopia19941994 99,329 5,752

Ethiopia19951995 39 26,034 9,040 8,888 7,763 343

Ethiopia19961996 39 41,889 13,160 15,471 12,472 786 2,534 101,746 37,206

Ethiopia19971997 48 59,105 15,957 24,594 17,512 1,042 45 208 253

Ethiopia19981998 64 69,472 18,864 27,845 22,142 621 162 459 621

Ethiopia19991999 63 72,095 21,597 27,648 22,266 688 181 411 592

Ethiopia20002000 85 91,101 30,510 30,565 28,907 1,119 252 577 829

Ethiopia20012001 70 94,957 33,028 28,561 31,179 1,320 326 543 869

Ethiopia20022002 95 110,289 36,541 33,308 38,798 1,642 709 36,541

Ethiopia20032003 95 117,600 39,698 35,141 40,883 1,878 242 434 39,698

Ethiopia20042004 70 123,127 41,430 37,119 0 42,477 2,101 424 672 41,430

Ethiopia20052005 90 124,262 38,525 39,816 43,675 2,246 313 560 38,525

ss+ indicates sputum smear-positive; ss-, sputum smear-negative; unk., sputum smear result unknown; re-treat., re-treatment; pulm.lab. confirmed, pulmonary case confirmed by positive smear or culture.

This sheet contains the data that you previously reported to WHO since 1980. It includes case notifications, age-sex, treatment outcomes, re-treatment outcomes, MDR-TB, TB-HIV and financial data. If you would like to update these data, please correct the numbers and highlight the updated cells.

Move to the right side to see more

Age-sex breakdown of new smear-positive cases

Male DOTS Female DOTS Male non-DOTS Female non-DOTSYear 0–14 15–24 25–34 35–44 45–54 55–64 65+ 0–14 15–24 25–34 35–44 45–54 55–64 65+ 0–14 15–24 25–34 35–44 45–54 55–64 65+ 0–14 15–24 25–34 35–44 45–54 55–64 65+

1980

1981

1982

1983

1984

1985

1986

1987

1988

1989

1990

1991

1992

1993

1994

1995 247 1,221 1,017 541 276 142 51 283 908 781 382 152 64 15

1996 302 1,739 1,609 854 427 201 71 369 1,564 1,147 576 246 88 32

1997 579 2,810 2,520 1,365 736 401 193 687 2,469 2,173 1,039 481 192 108

1998 715 2,643 3,187 1,610 839 429 171 832 3,016 2,434 1,220 519 194 55

1999 692 3,916 3,673 1,925 1,045 471 230 798 3,310 2,949 1,539 713 225 69

2000 915 5,095 5,187 3,082 1,495 610 397 1,037 4,699 4,424 2,105 976 366 122

2001 913 5,730 5,594 3,233 1,581 742 354 1,107 5,109 4,830 2,372 1,014 338 111

2002 1,251 6,764 5,669 3,128 1,544 821 372 1,614 5,607 5,692 2,685 935 323 136

2003 1,110 6,923 6,648 3,737 2,022 976 483 1,387 5,936 5,908 2,780 1,239 412 137

2004 1,160 7,167 7,002 4,060 1,988 911 456 1,367 6,422 6,091 2,984 1,284 414 124

2005 1,109 6,726 6,181 3,454 1,985 1,027 475 1,326 5,885 5,663 2,730 1,296 513 155

Drug resistance TB TB/HIV

Year GLC Other GLC Other GLC Other GLC Other GLC Other

1980

1981

1982

1983

1984

1985

1986

1987

1988

1989

1990

1991

1992

1993

1994

1995

1996

1997

1998

1999

2000

2001

2002 nk nk nk nk

2003 n.k. 0

2004

2005 3,211 1,321 1,166 388

How many laboratory-confirmed cases of MDR-TB were identified among new and re-treatment TB

patients diagnosed?

How many patients registered as "new" received DST at the start of

treatment?

How many of these patients were identified as MDR-TB based on DST at the start of treatment?

How many patients registered as "re-treatment" received DST at the

start of treatment?

How many of these patients were identified as MDR-TB based on DST at the start of treatment? How many TB patients

were tested for HIV?

Of those tested, how many were found to

be HIV-positive?

Of those found to be HIV-positive, how many started co-

trimoxazole preventive therapy?

Of those found to be HIV-positive, how many

started ART?

Please provide the final data for 2005 TB-HIV data in the sheet N_otifications".

The WHO has been asking for some of the TB-HIV data for more than one time in two consequent years (e.g. asking for 2003 data in 2004 and 2005). Some countries reported different numbers for the same indicator and the same period. Therefore, in some of the cells uner TB-HIV heading, you might find more than one number separated by space. Please provide the final number by overwriting the cells that have more than one number and highlight the updated cells.

Treatment outcomesNew smear-positive DOTS New smear-positive non-DOTS New pulmonary lab-confirmed DOTS New pulmonary lab-confirmed non-DOTS

Compl- Trans- Compl- Trans- Compl- Trans- Compl- Trans-

Year Registered Cured eted Died Failed Defaulted ferred Registered Cured eted Died Failed Default ferred Registered Cured eted Died Failed Defaulted ferred Registered Cured eted Died Failed Default ferred

1980

1981

1982

1983

1984

1985

1986

1987

1988

1989

1990

1991

1992 1,242 752 91 58 17 294 30

1993 2,171 1,391 86 143 38 381 132

1994 2,933 2,080 91 202 47 389 124

1995 5,087 2,836 245 279 89 657 201

1996 8,442 5,561 637 598 116 1,061 469 2,534 1,063 544 166 38 527 30

1997 11,592 7,099 1,209 767 111 1,352 541

1998 14,836 8,043 2,908 933 147 1,985 644

1999 15,980 9,641 2,503 1,082 156 1,543 637 4,531 1,288 1,773 175 37 837 218

2000 29,662 18,705 5,061 1,834 356 2,571 1,041

2001 32,391 19,814 4,718 2,146 256 1,938 1,197

2002 36,541 21,560 6,298 2,396 259 1,820 3,586

2003 39,698 21,560 6,298 2,396 259 1,820 1,591

2004 41,430 26,460 6,411 2,555 303 1,957 2,090

Re-treatment outcomesDOTS, unspecified re-treatment DOTS, relapse DOTS, after failure DOTS, after default

Compl- Trans- Compl- Trans- Compl- Trans- Compl- Trans-

Year Registered Cured eted Died Failed Defaulted ferred Registered Cured eted Died Failed Default ferred Registered Cured eted Died Failed Defaulted ferred Registered Cured eted Died Failed Default ferred

1980

1981

1982

1983

1984

1985

1986

1987

1988

1989

1990

1991

1992

1993

1994 101 76 2 8 2 9 4

1995 193 137 16 6 9 15 10

1996 481 258 82 27 20 55 28

1997 784 409 134 65 31 104 41

1998 758 350 104 64 21 56 25

1999 846 501 127 73 25 85 35

2000 1,556 931 168 155 66 120 60

2001 1,505 826 142 103 46 85 37

2002 1,716 889 148 118 48 91 42

2003 1,716 889 148 118 48 91 42

2004 3,197 1,222 502 280 69 146 104

Utilization of health services

Year

1980

1981

1982

1983

1984

1985

1986

1987

1988

1989

1990

1991

1992

1993

1994

1995

1996

1997

1998

1999

2000

2001

2002

2003

2004 62 62 10 5-7% 15 days 1 month 830

2005

Typical number of visits to a health facility required for one

new smear-positive patient after diagnosis is made

Typical number of visits to a health facility required for a new smear negative/extra-pulmonary patient after diagnosis is made

Estimated percentage of new smear-positive patients that are

hospitalized

Estimated percentage of new smear negative/extra-pulmonary

patients that are hospitalized

Estimated average duration of stay for new smear-positive

patients if hospitalized (days)

Estimated average duration of stay for new smear

negative/extra-pulmonary patients if hospitalized (days)

Number of hospital beds used exclusively for TB (including beds in sanatoria, where these exist)

Financial dataBudget data (US $) Expenditure data (US $)

BUDGET REQUIRED

EXPECTED Funding RECEIVED FundingGovernment Loans GFATM Other Grants GAP Government Loans GFATM Other Grants

TB drugs: first-line

2002

2,800,000

TB drugs: second-line (for MDR-TB) 0

Staff working exclusively for TB control (central unit staff and subnational TB coordinators) 300,000

Initiatives to increase case detection and cure rates 0

TB/HIV collaborative activities 0

Buildings, vehicles, equipment (lab / office equip. etc.) 1,000,000

All other budget lines for TB (e.g., training, fuel for supervision, supplies, recording and reporting) 700,000

TOTAL 4,800,000 1,100,000 0 0 3,700,000


2003

3,000,000 4,064,000 0 0 4,064,000 0

TB drugs: second-line (for MDR-TB) 0 0 0 0 0

Staff working exclusively for TB control (central unit staff and subnational TB coordinators) 200,000 50,000 50,000 0 0

Initiatives to increase case detection and cure rates 0 527,847 0 0 127,000 400,847

TB/HIV collaborative activities 0 498,280 0 0 419,000 79,280

Buildings, vehicles, equipment (lab / office equip. etc.) 3,600,000 1,908,000 500,000 0 1,408,000 0

All other budget lines for TB (e.g., training, fuel for supervision, supplies, recording and reporting) 3,800,000 1,311,000 0 0 1,000,000 311,000

TOTAL 10,600,000 2,200,000 0 0 8,400,000 0 8,359,127 550,000 0 7,018,000 791,127


2004

4,180,000 0 0 4,180,000 0 0 3,300,000 3,500,000

TB drugs: second-line (for MDR-TB) 0 0 0 0 0 0

Staff working exclusively for TB control (central unit staff and subnational TB coordinators) 50,000 50,000 0 0 0 0 43,000 50,000

Initiatives to increase case detection and cure rates 365,500 0 0 65,500 300,000 0 57,803 57,803

TB/HIV collaborative activities 534,000 0 0 334,000 200,000 0 234,976 190,000 275,000

Buildings, vehicles, equipment (lab / office equip. etc.) 945,500 500,000 0 420,500 25,000 0 2,172,694 1,550,000 622,694

All other budget lines for TB (e.g., training, fuel for supervision, supplies, recording and reporting) 706,000 0 0 370,000 336,000 0 888,500 1,040,462

TOTAL 6,781,000 550,000 0 5,370,000 861,000 0 6,696,973 50,000 5,297,803 1,938,156

ACTUAL EXPENDITURE

Financial dataBudget data (US $) Expenditure data (US $)

BUDGET REQUIRED

EXPECTED Funding RECEIVED FundingGovernment Loans GFATM Other Grants GAP Government Loans GFATM Other Grants


2005

4,700,000 4,200,000 500,000 4,460,789 4,526,000

TB drugs: second-line (for MDR-TB) 0

Staff working exclusively for TB control (central unit staff and subnational TB coordinators) 50,000 50,000 0

Initiatives to increase case detection and cure rates 100,000 15,000 85,000

TB/HIV collaborative activities 100,000 60,000 40,000

Buildings, vehicles, equipment (lab / office equip. etc.) 0

All other budget lines for TB (e.g., training, fuel for supervision, supplies, recording and reporting) 1,887,794 247,332 1,640,462 0

TOTAL 6,837,794 50,000 0 4,447,332 1,715,462 625,000 4,460,789 4,526,000


2006

4,200,000 4,200,000

Staff working exclusively for TB control (central unit staff and subnational TB coordinators) 207,000 207,000

Routine programme management and supervision activities 300,000 300,000

Laboratory supplies and equipment for smears, culture and DST 0 150,000

PPM (Public–Private Mix) and PAL 0

Collaborative TB/HIV activities 300,000 300,000

Second-line drugs for MDR-TB 0

Management of MDR-TB (budget excluding second-line drugs) 0

Advocacy, communication & social mobilization and community-based care 0

Operational research 0

All other budget lines for TB (e.g., technical assistance) 1,200,000 1,200,000

TOTAL 6,207,000 207,000 4,650,000 1,500,000 -150,000

ACTUAL EXPENDITURE

Financial dataBudget data (US $)

BUDGET REQUIRED

EXPECTED FundingGovernment Loans GFATM Other Grants GAP


2007

4,200,000 4,200,000 0

Staff working exclusively for TB control (central unit staff and subnational TB coordinators) 207,000 207,000 0

Routine programme management and supervision activities 0

Laboratory supplies and equipment for smears, culture and DST 300,000 300,000 0

PPM (Public–Private Mix) and PAL 0

Collaborative TB/HIV activities 300,000 300,000 0

Second-line drugs for MDR-TB 0

Management of MDR-TB (budget excluding second-line drugs) 0

Advocacy, communication & social mobilization and community-based care 50,000 20,000 30,000

Operational research 0

All other budget lines for TB (e.g., technical assistance) 1,200,000 1,200,000 0

TOTAL 6,257,000 207,000 4,500,000 1,520,000 30,000

Please provide the final data for 2007 budget in the sheet F_inance". Note some line items have been sub-divided, in order to collect more detailed information.

[xls] · web viewdpr korea dr congo ecuador egypt el salvador equatorial guinea eritrea estonia...

Documents